Multi-Dose Safety/Pharmacodynamic Study of SEL-212/SEL-037 in Subjects With Symptomatic Gout & Elevated Blood Uric Acid

An Open Label Phase II Multiple Dose Safety, Pharmacokinetic and Pharmacodynamics Study of SEL-212 Followed by Open Label Administration of SEL-037 in Subjects With Symptomatic Gout and Elevated Blood Uric Acid

This is an open label multicenter study to evaluate the safety and tolerability of multiple doses (3 monthly IV infusions) of SEL-212 ( a combination of pegsiticase (SEL-037) and SVP-rapamycin (SEL-110)) followed by multiple doses (2 monthly IV infusions) of pegsiticase (SEL-037) alone for a total of 5 treatment cycles in subjects with symptomatic gout and hyperuricemia. Additional participants will be treated with multiple doses ( 5 monthly IV infusions) of pegsiticase (SEL-037) alone.

Participants will be monitored for safety endpoints through the 5th treatment cycle plus 30 days .Pharmacokinetic samples will be drawn at pre-determined time points in addition to weekly serum uric acid levels.

Study Overview

• Status: Completed
• Conditions: Hyperuricemia; Gout Chronic
• Intervention / Treatment: Drug: SEL-037; Drug: SEL-212; Drug: SVP-rapamycin (SEL-110)

Detailed Description

This is an open label multicenter study to evaluate the safety and tolerability of multiple doses (3 monthly IV infusions) of SEL-212 ( a combination of pegsiticase ( SEL-037, also known as pegadricase) and SVP-rapamycin (SEL-110)) followed by multiple doses (2 monthly IV infusions) of pegsiticase (SEL-037) alone for a total of 5 treatment cycles in participants with symptomatic gout and hyperuricemia. Additional participants will be treated with multiple doses (5 monthly IV infusions) of pegsiticase (SEL-037) alone.

Uricase is an enzyme that converts uric acid to the readily soluble allantoin that is then excreted and SEL-110 is designed to prevent unwanted anti-drug-antibodies (ADAs) from forming. All participants will be monitored for safety and tolerability to drug throughout the study on a weekly schedule. Pharmacokinetic and pharmacodynamic parameters will at specific timepoints to monitor for continued efficacy. Pharmacodynamic parameters measured include uric acid levels and levels of ADAs.

The study duration per enrolled participant will be approximately 6 months including a 1 month screening period followed by 5 treatment cycles and an end of treatment visit which will occur 30 days after the last IV infusion .

• Study Type: Interventional
• Enrollment (Actual): 152
• Phase: Phase 2

Contacts and Locations

Study Locations

• United States
  • California
    • Anaheim, California, United States, 92801
      • Anaheim Clinical Trials
    • El Cajon, California, United States, 92020
      • Tri West Research Associates LLC
    • Irvine, California, United States, 92614
      • Irvine Center for Clinical Research Inc.
  • Florida
    • Clearwater, Florida, United States, 33765
      • Clinical Research of West Florida
    • DeBary, Florida, United States, 32713
      • Omega Research Consultants LLC
    • Orlando, Florida, United States, 32806
      • Compass Research LLC
  • Hawaii
    • Honolulu, Hawaii, United States, 96814
      • East-West Medical Research Institute
  • Idaho
    • Boise, Idaho, United States, 83642
      • Advanced Clinical Research
  • Kentucky
    • Louisville, Kentucky, United States, 40213
      • L-MARC
  • North Carolina
    • Greensboro, North Carolina, United States, 27410
      • Triad Clinical Trials LLC
  • Ohio
    • Cincinnati, Ohio, United States, 45242
      • New Horizons Clinical Research
  • Pennsylvania
    • Duncansville, Pennsylvania, United States, 16635
      • Altoona Center for Clinical Research
  • Utah
    • West Jordan, Utah, United States, 84088
      • Advanced Clinical Research

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 19 years to 73 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Adult (age 21-75 inclusive) men and women of non child bearing potential with established or symptomatic gout which is defined as having at least ONE of any of the 3 following factors:

   1. ≥ 1 tophus
   2. 1 gout flare within the last 6 months
   3. Chronic gouty arthropathy
2. Screening serum uric acid of >6 mg/dL
3. On a gout flare prophylactic regimen for 7 days prior to first dose
4. Willing to provide written informed consent prior to first study procedure is performed.
5. Understands and is willing and able to comply with study requirements, including the schedule of follow-up visits.

Exclusion Criteria:

1. History of anaphylaxis or severe allergic reaction.
2. History of an allergy to pegylated products.

3. Women of child bearing potential, Defined as:

   • <6 weeks after surgical bilateral salpingooperhectony with or without hysterectomy
   • Pre or perimenopausal ( < less than 24 months of natural amenorrhea)
4. Initiation or change in dose of hormone-replacement therapy for menopausal women less than 1 month prior to the Screening Visit or during the Screening Phase would be exclusionary. If after being on a stable dose of hormone-replacement therapy for one month the patient may be considered for the study if she continues to meet all other inclusion and exclusion criteria
5. Uncontrolled diabetes with baseline HbA1c ≥8%;
6. Glucose-6-phosphate dehydrogenase deficiency;
7. Uncontrolled hypertension
8. Ongoing treatment for arrhythmia, including placement of an implantable defibrillator;
9. History of coronary artery disease, including myocardial infarction;
10. Congestive heart failure, New York Heart Association Class III or IV;
11. ECG with evidence of prior myocardial infarction, clinically significant arrhythmia, or other abnormalities that, in the opinion of the investigator, are consistent with significant underlying cardiac disease;
12. History of hematological or autoimmune disorders, is immunosuppressed or immunocompromised;
13. Prior exposure to any experimental or marketed uricase (e.g., rasburicase (Elitek, Fasturtec), pegloticase (Krystexxa®), pegsiticase (SEL-037)
14. History of malignancy within the last 5 years other than basal skin cancer;
15. Subjects who, in the opinion of the investigator, present with a condition that would compromise their safety or that would make study completion unlikely.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

14

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: SEL-037 Pegadricase LD (low dose) alone; Pegadricase 0.2 mg/kg intravenous (IV) every 28 days for 5 treatments	Drug: SEL-037; SEL-037, biologic; Other Names: Pegadricase
Experimental: SEL-037 Pegadricase HD (high dose) alone; Pegadricase 0.4 mg/kg intravenous (IV) every 28 days for 5 treatments	Drug: SEL-037; SEL-037, biologic; Other Names: Pegadricase
Experimental: SEL-212, Pegadricase LD & SEL-110 (1a); Pegadricase 0.2 mg/kg IV plus SEL-110 0.05 mg/kg IV every 28 days for 3 treatments, followed by pegadricase 0.2 mg/kg IV every 28 days for 2 treatments	Drug: SEL-212; SEL-212, biologic; Other Names: Pegadricase plus SVP-rapamycin; Drug: SVP-rapamycin (SEL-110); SVP-rapamycin, biologic; Other Names: SEL-110
Experimental: SEL-212, Pegadricase HD & SEL-110 (1b); Pegadricase 0.4 mg/kg IV plus SEL-110 0.05 mg/kg IV every 28 days for 3 treatments, followed by pegadricase 0.4 mg/kg IV every 28 days for 2 treatments	Drug: SEL-212; SEL-212, biologic; Other Names: Pegadricase plus SVP-rapamycin; Drug: SVP-rapamycin (SEL-110); SVP-rapamycin, biologic; Other Names: SEL-110
Experimental: SEL-212, Pegadricase LD & SEL-110 (2a); Pegadricase 0.2 mg/kg IV plus SEL-110 0.08 mg/kg IV every 28 days for 3 treatments, followed by pegadricase 0.2 mg/kg IV every 28 days for 2 treatments	Drug: SEL-212; SEL-212, biologic; Other Names: Pegadricase plus SVP-rapamycin; Drug: SVP-rapamycin (SEL-110); SVP-rapamycin, biologic; Other Names: SEL-110
Experimental: SEL-212, Pegadricase HD & SEL-110 (2b); Pegadricase 0.4 mg/kg IV plus SEL-110 0.08 mg/kg IV every 28 days for 3 treatments, followed by pegadricase 0.4 mg/kg IV every 28 days for 2 treatments	Drug: SEL-212; SEL-212, biologic; Other Names: Pegadricase plus SVP-rapamycin; Drug: SVP-rapamycin (SEL-110); SVP-rapamycin, biologic; Other Names: SEL-110
Experimental: SEL-212, Pegadricase HD & SEL-110 (3a); Pegadricase 0.2 mg/kg IV plus SEL-110 0.1 mg/kg IV every 28 days for 3 treatments, followed by pegadricase 0.2 mg/kg IV every 28 days for 2 treatments	Drug: SEL-212; SEL-212, biologic; Other Names: Pegadricase plus SVP-rapamycin; Drug: SVP-rapamycin (SEL-110); SVP-rapamycin, biologic; Other Names: SEL-110
Experimental: SEL-212, Pegadricase HD & SEL-110 (3b); Pegadricase 0.4 mg/kg IV plus SEL-110 0.1 mg/kg IV every 28 days for 3 treatments, followed by pegadricase 0.4 mg/kg IV every 28 days for 2 treatments	Drug: SEL-212; SEL-212, biologic; Other Names: Pegadricase plus SVP-rapamycin; Drug: SVP-rapamycin (SEL-110); SVP-rapamycin, biologic; Other Names: SEL-110
Experimental: SEL-212, Pegadricase HD & SEL-110 (4a); Pegadricase 0.4 mg/kg IV plus SEL-110 0.125 mg/kg IV every 28 days for 3 treatments, followed by pegadricase 0.4 mg/kg IV every 28 days for 2 treatments	Drug: SEL-212; SEL-212, biologic; Other Names: Pegadricase plus SVP-rapamycin; Drug: SVP-rapamycin (SEL-110); SVP-rapamycin, biologic; Other Names: SEL-110
Experimental: SEL-212, Pegadricase HD & SEL-110 (4b); Pegadricase 0.2 mg/kg IV plus SEL-110 0.15 mg/kg IV every 28 days for 3 treatments, followed by pegadricase 0.2 mg/kg IV every 28 days for 2 treatments	Drug: SEL-212; SEL-212, biologic; Other Names: Pegadricase plus SVP-rapamycin; Drug: SVP-rapamycin (SEL-110); SVP-rapamycin, biologic; Other Names: SEL-110
Experimental: SEL-212, Pegadricase HD & SEL-110 (5a); Pegadricase 0.4 mg/kg IV plus SEL-110 0.15 mg/kg IV every 28 days for 3 treatments, followed by pegadricase 0.4 mg/kg IV every 28 days for 2 treatments	Drug: SEL-212; SEL-212, biologic; Other Names: Pegadricase plus SVP-rapamycin; Drug: SVP-rapamycin (SEL-110); SVP-rapamycin, biologic; Other Names: SEL-110
Experimental: SEL-212, Pegadricase HD & SEL-110 (5b); Pegadricase 0.2 mg/kg IV plus SEL-110 0.15 mg/kg IV every 28 days for 5 treatments	Drug: SEL-212; SEL-212, biologic; Other Names: Pegadricase plus SVP-rapamycin; Drug: SVP-rapamycin (SEL-110); SVP-rapamycin, biologic; Other Names: SEL-110
Experimental: SEL-212, Pegadricase HD & SEL-110 (6a); Pegadricase 0.2 mg/kg IV plus SEL-110 0.10 mg/kg IV every 28 days for 1 treatment followed by pegadricase 0.2 mg/kg IV plus SEL-110 0.15 mg/kg IV every 28 days for 4 treatments	Drug: SEL-212; SEL-212, biologic; Other Names: Pegadricase plus SVP-rapamycin; Drug: SVP-rapamycin (SEL-110); SVP-rapamycin, biologic; Other Names: SEL-110
Experimental: SEL-212, Pegadricase HD & SEL-110 (6b); Pegadricase 0.2 mg/kg IV plus SEL-110 0.1 mg/kg IV every 28 days for 5 treatments	Drug: SEL-212; SEL-212, biologic; Other Names: Pegadricase plus SVP-rapamycin; Drug: SVP-rapamycin (SEL-110); SVP-rapamycin, biologic; Other Names: SEL-110

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Safety and Tolerability of Multiple Intravenous Infusions of SEL-037 or SEL-212 as Assessed by the Percentage of Participants Experiencing Serious Adverse Events and Those Adverse Events Reported by 5 Percentage or More in the Safety Analysis Set	To determine the safety and tolerability of SEL-037 (pegadricase) after up to 5 monthly infusions, of SEL-212 for 3 monthly infusions followed by 2 monthly infusions of SEL-037 (pegadricase), or of SEL-212 for 5 monthly infusions as assessed by the percentage of participants in a treatment arm experiencing serious adverse events and percentage of participants experiencing those adverse events that were reported by 5 or more percentage of participants in any arm in the safety analysis set	Five monthly infusions

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of Participants With Reduced Serum Uric Acid After Multiple Monthly IV Infusions With or Without SEL-110	Measurement of the number of participants with reduced serum uric acid after multiple monthly infusions with or without SEL-110 as determined by values of sUA < 6 mg/dL at the end of Treatment Period 3 and at the end of Treatment Period 5 in eligible subjects	3 and 5 months

Collaborators and Investigators

• Sponsor: Selecta Biosciences, Inc.

Study record dates

Study Major Dates

• Study Start (Actual): October 1, 2016
• Primary Completion (Actual): December 1, 2018
• Study Completion (Actual): January 1, 2019

Study Registration Dates

• First Submitted: November 6, 2016
• First Submitted That Met QC Criteria: November 8, 2016
• First Posted (Estimate): November 9, 2016

Study Record Updates

• Last Update Posted (Actual): February 14, 2022
• Last Update Submitted That Met QC Criteria: January 31, 2022
• Last Verified: January 1, 2022

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Metabolic Diseases; Genetic Diseases, Inborn; Joint Diseases; Musculoskeletal Diseases; Rheumatic Diseases; Arthritis; Metabolism, Inborn Errors; Crystal Arthropathies; Purine-Pyrimidine Metabolism, Inborn Errors; Hyperuricemia; Gout; Physiological Effects of Drugs; Anti-Infective Agents; Antineoplastic Agents; Immunosuppressive Agents; Immunologic Factors; Anti-Bacterial Agents; Antibiotics, Antineoplastic; Antifungal Agents; Sirolimus
• Other Study ID Numbers: SEL-212/201

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No